# US 2019/0314370 A1 · Arylamide compounds and compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314370 A1
- Document ID: US20190314370A1
- Status: Published application
- Kind: A1
- Application number: 16/188,904
- Filed: 2018-11-13
- Published: 2019-10-17
- Earliest claimed: 2006-12-29
- Assignees: Innovation Pharmaceuticals Inc.
- Applicants: Innovation Pharmaceuticals Inc.
- Inventors: Richard W. Scott
- Web page: https://patentgrep.com/patent/US20190314370A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0046: {Ear}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/74: Synthetic polymeric materials
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 9/12: Antihypertensives
- A61P 23/00: Anaesthetics
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/02: not condensed with other rings
- C07D 239/24: having three or more double bonds between ring members or between ring members and non-ring members
- C07D 239/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 403/14: containing three or more hetero rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method a treating a bacterial infection in a mammal comprising administering to the mammal in need thereof an effective amount of a pharmaceutical composition comprising a compound having the formula
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The method of claim 16 wherein the composition further comprises Tris-buffered saline.

### Claim 18 (depends on 16)

The method of claim 16 wherein the composition further comprises Farnesol, polyethylene glycol, and Tris-buffered saline.

### Claim 19 (depends on 16)

The method of claim 16 wherein the composition further comprises an additional medicament.

### Claim 20 (depends on 19)

The method of claim 19 wherein the additional medicament is chosen from an antibiotic, an anti-inflammatory agent, an anesthetic agent, an anti-allergic agent, an acetylcholine blocking agent, an adrenergic agonist, a beta-adrenergic blocking agent, an anti-glaucoma agent, and an anti-hypertensive agent.

### Claim 21 (depends on 20)

The method of claim 20 wherein the antibiotic is chosen from an aminoglycoside, a cephalosporin, a diaminopyridine, a fluoroquinolone, a sulfonamide, and a tetracycline.

### Claim 22 (depends on 20)

The method of claim 20 wherein the antibiotic is chosen from amikacin, azithromycin, cefixime, cefoperazone, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone, chloramphenicol, ciprofloxacin, clindamycin, colistin, domeclocycline, doxycycline, erythromycin, gentamicin, mafenide, methacycline, minocycline, neomycin, norfloxacin, ofloxacin, oxytetracycline, polymyxin B, pyrimethamine, silver sulfadiazine, sulfacetamide, sulfisoxazole, tetracycline, tobramycin, and trimethoprim.

### Claim 23 (depends on 20)

The method of claim 20 wherein the anti-inflammatory agent is a steroidal agent or a non-steroidal agent.

### Claim 24 (depends on 23)

The method of claim 23 wherein the steroidal agent is chosen from dexamethasone, rimexolone, prednisolone, fluorometholone, and hydrocortisone, and wherein the non-steroidal agent is chosen from a cyclooxygenase type I or type II inhibitor, a PAF antagonist, a PDE IV inhibitor, and an inhibitor of cytokine production.

### Claim 25 (depends on 24)

The method of claim 24 wherein the cyclooxygenase type I or type II inhibitor is chosen from diclofenac, flurbiprofen, ketorolac, suprofen, nepafenac, amfenac, indomethacin, naproxen, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, mefanamic acid, diflusinal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone, aspirin, oxyphenbutazone, tenoxicam, carprofen, vioxx, celecoxib, and etodolac.

### Claim 26 (depends on 24)

The method of claim 24 wherein the PAF antagonist is chosen from apafant, bepafant, minopafant, nupafant, and modipafant.

### Claim 27 (depends on 24)

The method claim 24 wherein the PDE IV inhibitor is chosen from ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, and roflumilast.

### Claim 28 (depends on 20)

The method claim 20 wherein the anti-allergic agent is pemirolast or olopatadine.

### Claim 29 (depends on 20)

The method of claim 20 wherein the anti-allergic agent is a corticosteroid.

### Claim 30 (depends on 29)

The method of claim 29 wherein the corticosteroid is chosen from prednisolone, fluorometholone, loteprenol, and dexamethasone.

### Claim 31 (depends on 16)

The method of claim 16 wherein the pharmaceutically acceptable salt is a hydrochloride acid addition salt.

### Claim 32 (depends on 16)

The method of claim 16 wherein the bacteria is chosen from fluoroquinolone-susceptible Staphylococcus aureus, fluoroquinolone-resistant Staphylococcus aureus, fluoroquinolone-susceptible and coagulase-negative Staphylococcus epidermidis, fluoroquinolone-resistant and coagulase-negative Staphylococcus epidermidis, Staphylococcus pneumonia, Moraxella catarrhalis, Staphylococcus viridans, Serratia marcescens, Pseudomonas aereginosa, and Haemophilus influenza.
